Project Grant R43AI172557
Award Date 8/1/22
Completion Date 1/31/24
Dollars Obligated $300K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant, awarded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $274,991 to Duravax Inc. to develop thermostable formulations of mRNA vaccines and therapeutics. The project aims to overcome the cold-chain limitations of current mRNA products by demonstrating the feasibility of storing mRNA APIs and mRNA-lipid nanoparticles at room temperature for extended periods. If...
- Federal Cooperative Agreement Summary Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) for an NSF Small Business Innovation Research (SBIR) Phase II project beginning July 1, 2025 and concluding June 30, 2027. The project is based in Cypress, California and focuses on developing stable prophylactic antibodies (SPABs) to address infectious diseases for which existing...
- This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
- Federal Grant Award Summary Via Therapeutics, LLC received a $314,363 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 11, 2025, with completion targeted for August 31, 2026. The company is developing a microneedle-based messenger RNA (mRNA) influenza vaccine utilizing proprietary thin-film freeze-drying technology to enable non-invasive, transcutaneous...
- The National Science Foundation awarded a $275,000 STTR Phase I grant to Inaedis, Inc. to develop an innovative method for the thermal stabilization of biopharmaceutical formulations. The project aims to establish a rapid room-temperature aerosol dehydration (RTAD) process that improves the stability of biologics, vaccines, and other pharmaceuticals, circumventing the need for a cold chain supply. This technology seeks to serve international markets by allowing the pharmaceutical industry to...
- This $249,999 National Science Foundation project grant supports the development of a bioengineered nanobarrier spray to protect against SARS-CoV-2 and other viral infections of the nasopharynx. Funded under the NSF Engineering program (CFDA 47.041), the two-year award to the University of Southern California will support computational modeling of nanobarrier delivery via nasal applicator as well as efficacy testing in a coronavirus mouse model. Specifically, the university researchers will...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- Federal Grant Award Summary The National Science Foundation (NSF) awarded Immuno Nano Med, Inc. a Small Business Technology Transfer (STTR) Phase I Project Grant of $305,000 on October 1, 2025, under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). The award, with performance in Ames, Iowa, supports development of a room-temperature-stable, dry powder inhalable influenza vaccine designed to eliminate current vaccine delivery limitations. The project will demonstrate...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a $676,666 Project Grant on September 3, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an advanced influenza messenger ribonucleic acid (mRNA) vaccine delivery system. The research will focus on constructing a trivalent self-amplifying mRNA flu vaccine encapsulated within liposomes and delivered via a microneedle array...
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...